A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART
This study has been completed.
Information provided by:
First received: July 17, 2007
Last updated: November 30, 2010
Last verified: November 2010
To investigate how common it is that patients using Symibort SMART take high average daily doses that are not considered appropriate by their physician (overuse) or are hospitalised due to their asthma at least partly due to underuse.
||Observational Model: Case-Only
Time Perspective: Prospective
||A Pharmaceopidemiological Study in Patients Who Use Symbicort Turbuhaler as Maintenance and Reliever Therapy (Symbicort SMART) Capturing Over Use and Under Use Via the General Practice Research Database
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||May 2010 (Final data collection date for primary outcome measure)
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Population comes from Primary Care Clinics and Pulmonary Experts
- Asthma diagnosis, patient registered with the prescribing physician for at least one year before the qualifying prescription of Symbicort, prescription of Symbicort SMART after UK launch of the concept
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00503061
|London, United Kingdom |
||Catriona McMahon, MD
||AZ UK MC
||Tomas Andersson, MD
||AZ R&D Lund
No publications provided
||Tomas Andersson, MSD, AstraZeneca Pharmaceuticals
History of Changes
|Other Study ID Numbers:
|Study First Received:
||July 17, 2007
||November 30, 2010
||United Kingdom: Independent Scientific Advisory Committee
Keywords provided by AstraZeneca:
ClinicalTrials.gov processed this record on March 26, 2015